With the epidemic of 2019 novel coronavirus, COVID-19 has spread rapidly from Wuhan throughout the country during the past few months. In recent days, it is reported to be spreading in many other countries including Korea, Japan, Italy, etc. According to WHO’s report [1], there’s already 79,331 confirmed cases globally, in which 77,262 are from China) until 25th Feb 2020. NCP is a highly contagious disease characterised by a long incubation period and its onset of concealment. This disease has already called attention worldwide. And Chinese government reacted quickly with six versions publication of programme for the diagnosis and treatment of the disease. As everyone might have noticed, CT was recommended as the major evidence of clinical diagnosis in HuBei province by the National Health and Health Commission of China 5th edition in Feb 5th 2020 [2] but had been eliminated by the next edition on Feb 19th 2020 [3]. One might be interested in the background of this action. As we all know, RT-PCR assay is the gold standard of COVID-19 diagnosis, however its high false negative detection rate (30-50%) due to sampling position and possible low virus load hinders its validation during a special period of time [4]. Several previous reports had already reviewed RT-PCR negative patient cohorts with CT positive results [5, 6].While, Initial CT, as reported, yielded much higher detection rate (98%) of COVID-19 than first RT-PCR (71%) (P < 0.001) [7].
展开▼
